

# Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With *ATM*-Mutated Glioblastoma and *MSH6*-Deficient Lynch Syndrome

Danielle M. File, MD<sup>1</sup>; Katherine P. Morgan, PharmD, BCOP, CPP<sup>2</sup>; and Simon Khagi, MD<sup>1,3</sup>

## INTRODUCTION

Glioblastoma (GBM) remains a life-limiting disease with a median overall survival of 14.6 months.<sup>1</sup> Prognosis is improved in patients who undergo gross total resection and those whose tumors demonstrate O6-methylguanine-DNA methyltransferase (*MGMT*) promoter methylation and isocitrate dehydrogenase (*IDH*) mutations.<sup>2-4</sup>

Given that GBM commonly recurs within 2 years, there is a clear rationale for improving upfront therapy. Poly (ADP-ribose) polymerase inhibitors (PARPi) represent one approach, as investigated in previous studies using olaparib.<sup>5-7</sup>

We describe a patient with an unresectable *MGMT* unmethylated, *IDH* wild-type GBM. Tumor genomic profiling and germline results provided rationale for the addition of olaparib to standard therapy. The patient had a remarkable response, with an ongoing near-total absence of radiographic disease 2 years beyond diagnosis. Her consent was obtained for publication of this article.

## CASE

A 52-year-old female with suspected Lynch syndrome on the basis of family history and a personal history of endometrial cancer as well as premalignant breast and colon lesions presented with neurologic complaints. Magnetic resonance imaging revealed a 2.7 × 1.9-cm T2 hyperintense cortically based mass in the inferomedial right frontal lobe, which was determined to be unresectable because of bihemispheric involvement. *MGMT* promoter was unmethylated, and no *IDH* mutations were detected. The patient was enrolled in an observational clinical study (sponsored by Strata Oncology, Ann Arbor, MI), through which whole-exome and RNA sequencing on formalin-fixed paraffin-embedded tumor tissue revealed loss-of-function mutations in *ATM* and tumor protein 53 (*TP53*). The tumor was classified as tumor mutational burden (TMB) high, programmed death-ligand 1 (PD-L1) low, and microsatellite stable (MSS; Table 1). After completion of therapy, additional review of the

patient's records revealed a germline *MSH6* loss-of-function mutation, which confirmed Lynch syndrome.

The genomic findings and high likelihood of Lynch syndrome, along with early-phase data suggesting safety and brain penetration, provided rationale for the treating oncologist to initiate olaparib with standard chemoradiation. Olaparib was dosed at 150 mg daily for 3 consecutive days each week during chemoradiation. After chemoradiation, the patient received 6 cycles of maintenance temozolomide. She was also treated with alternating tumor-treating fields (Optune; Novocure, St Helier, Jersey), an externally applied, low-intensity electromagnetic field treatment shown to improve survival by 4.9 months over maintenance temozolomide alone when used 18 hours per day.<sup>8</sup> Device compliance was limited, and treatment was discontinued after 1 month. She has received no additional therapy.

Treatment was well tolerated. Interval imaging showed continued tumor shrinkage (Fig 1). Two years since diagnosis, further reduction in size was observed, compatible with ongoing partial response by RECIST. The patient remains fully functional.

## MOLECULAR TUMOR BOARD DISCUSSION

Given the excellent response in the setting of germline and somatic mutations in DNA repair genes, this patient was discussed at the institutional multidisciplinary molecular tumor board (MTB). The objective was to broaden the understanding of the impact of the mutations individually and collectively with respect to susceptibility to chemotherapy, radiation, and PARPi.

### Germline *MSH6* p.F1088Sfs\*2 Mutation; MSS

Pathogenic; loss of function (exon 5).

The presence of this mutation was not known at the time of treatment because it was not reported on the tumor sequencing report. Outside hospital records included this finding on germline testing performed by Ambry Genetics (Aliso Viejo, CA).

*MSH6* is involved in DNA mismatch repair (Appendix Table A1). A deleterious mutation constitutes Lynch

## ASSOCIATED CONTENT

### Appendix

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on May 28, 2020 and published at [ascopubs.org/journal/po](https://ascopubs.org/journal/po) on July 23, 2020; DOI <https://doi.org/10.1200/P0.20.00112>

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License



**TABLE 1.** Sequencing Results

Mutation Type	Mutations Identified	Predicted Consequence	Pertinent Negatives	Sequencing Platform
Germline	<i>MSH6</i> p.F1088Sfs*2	Loss of function	<i>ATM</i> , <i>BRCA1</i> , <i>BRCA2</i> , <i>TP53</i>	NGS or Sanger sequencing by Ambry Genetics
Somatic	<i>ATM</i> p.G1016X (VAF 45%)	Loss of function	<i>MSH6</i> <sup>a</sup>	NGS by Strata Oncology
	<i>TP53</i> p.R181H (VAF 39%)	Reduced function		
	<i>TP53</i> p.R248Q (VAF 45%)	Loss of function		
	PD-L1 low (RNA expression score 7)			NGS (PD-L1 expression reported as an RNA expression score, predictive of TPS)
	MSS			NGS (on the basis of length variant allele counts at multiple microsatellite loci)
	TMB high (69 mutations/MB)			NGS (on the basis of noncoding and coding, synonymous and nonsynonymous, and single-nucleotide and multinucleotide variants present at > 10% VAF)

Abbreviations: MB, megabase; MSS, microsatellite stable; NGS, next-generation sequencing; PD-L1, programmed death-ligand 1; TMB, tumor mutational burden; TPS, tumor proportion score; VAF, variant allele frequency.

<sup>a</sup>On initial report.

syndrome and results in high susceptibility to mutations in tumor suppressor and proto-oncogenes, which lead to a fourfold increased risk of primary brain tumors.<sup>9,10</sup> Germline *MSH6* mutations are rare in GBM. Most mutations are somatic, found almost exclusively after temozolomide therapy.<sup>11</sup> In this setting, they are associated with resistance to alkylating agents, hypothesized to be the dominant mechanism of acquired temozolomide resistance after therapy, likely because of failure of temozolomide-induced DNA damage to result in apoptosis in mismatch repair-deficient (dMMR) cells.<sup>12-24</sup> When *MSH6* mutations are present in treatment-naïve patients with *MGMT* methylated, otherwise chemosensitive tumors, treatment response is markedly attenuated.<sup>13</sup> Beyond treatment resistance, ongoing temozolomide exposure after *MSH6* inactivation leads to a hypermutator phenotype and tumor progression.<sup>14-16</sup> PARPi restore sensitivity to temozolomide in dMMR cells.<sup>25</sup> dMMR cells may also have increased resistance to radiotherapy.<sup>26-28</sup>

Lynch syndrome was not identified by somatic testing. Often, Lynch syndrome is discovered after a tumor is found to be microsatellite instability high (MSI-h) or dMMR on immunohistochemistry. *MSH6*-mutated brain tumors, however, are often not MSI-h by standard polymerase chain reaction testing, and immunohistochemistry is not standardly performed.<sup>29</sup> In this case, MSS status was determined from next-generation sequencing (NGS) on the basis of length variant allele counts at multiple microsatellite loci. While alternate NGS methods have demonstrated sensitivity and specificity in brain tumors, the performance of this specific methodology in GBM is unknown.<sup>30,31</sup> While deficient *MSH6* immunohistochemical staining would confirm a pathogenic mutation, intact

staining would not rule out dMMR because some mutations result in intact expression of dysfunctional protein.<sup>32-35</sup>


The *MSH6* mutation was not reported by somatic testing because of its presence in a stretch of repeating cytosines, known as a homopolymer region. Determination of nucleotide calls in homopolymer regions is a common source of sequencing errors in NGS, regardless of the platform used. Most laboratories do not report findings from homopolymer regions because of the uncertainty in base calling that occurs when repeating identical bases incorporate during the same synthesis cycle.<sup>27</sup> After the germline *MSH6* mutation was discovered, Strata Oncology was able to detect the mutation in the tumor sample with 94% allele frequency.

#### ***ATM* p.G1016X Mutation**

Likely pathogenic; nonsense (premature stop codon in exon 20/63).

There were no reports of this mutation in the queried databases; however, it is a predicted loss-of-function mutation that is based on other pathogenic mutations in a similar gene region. *ATM* is mutated in < 5% of glioblastomas.<sup>36</sup>

*ATM* is involved in DNA damage response (DDR; Appendix Table 1). Unlike dMMR, which prevents damaged cells from undergoing apoptosis, decreasing treatment efficacy, *ATM* mutations increase cell vulnerability to cytotoxic therapy.<sup>37</sup> They are associated with increased platinum sensitivity and superior survival.<sup>37,38</sup> Tumors with loss-of-function *ATM* mutations have increased radiosensitivity.<sup>39</sup> *ATM* suppression in the setting of p53 deficiency sensitizes tumors to DNA-damaging chemotherapy and radiotherapy, whereas *ATM* suppression with intact p53 leads to a worse response.<sup>40,41</sup>



**FIG 1.** Magnetic resonance imaging (MRI) of glioblastoma at the time of diagnosis (left). Glioblastoma was noted to be smaller after initial treatment with chemoradiation and olaparib and was further reduced in size after maintenance temozolomide. On the most recent MRI (right), obtained > 14 months after completion of therapy, the tumor demonstrated further regression, compatible with a durable, near-complete treatment response. TMZ, temozolomide.

Inactivating mutations in *ATM* result in DDR-deficient tumors that are susceptible to synthetic lethality with DNA-damaging agents and PARPi.<sup>42,43</sup> In the absence of data, it may be predicted that a tumor both dMMR and DDR deficient is exceptionally unstable and susceptible to synthetic lethality, although the complexity of the roles of *MSH6* and *ATM* in DNA repair and apoptosis make this uncertain.

#### ***TP53* p.R181H and p.R248Q**

Potential clinical significance; missense.

*TP53* encodes the p53 tumor suppressor protein and is mutated in > 30% of GBMs<sup>36,44</sup> (Appendix Table A1). *TP53* p.R181H disrupts protein function but may allow partial residual protein activity.<sup>45</sup> *TP53* p.R248Q is reported in > 380 CNS tumors associated with protein loss of function.<sup>45</sup> As previously mentioned, p53-deficient cells may be particularly vulnerable to DNA-damaging treatment when an *ATM* mutation is present. Conversely, the combination of dMMR and p53-deficient cells worsens response because of failed phosphorylation of p53 and, thus, failed cell arrest after treatment-induced DNA damage.<sup>46</sup> In general, cancers with mutant p53 have reduced sensitivity to chemotherapy and radiation; however, there are many instances where mutant p53 has no effect or even enhances treatment effect.<sup>47</sup>

#### **TMB High**

TMB was determined from NGS and included noncoding and coding, synonymous and nonsynonymous, and single-nucleotide and multinucleotide variants present at > 10% variant allele frequency. The high TMB is likely secondary to the *MSH6* mutation and resultant tumor

genome hypermutation.<sup>14,48-50</sup> In treated patients, hypermutation can result from exposure to alkylating agents.<sup>51</sup> The therapeutic implications of high TMB are not fully understood. Cancers with high TMB as a result of prior alkylator exposure are resistant to alkylators, but it is not clear whether tumors with high TMB from alternate etiologies share this resistance.<sup>51</sup>

#### **PD-L1 Low**

PD-L1 expression is used to predict response to immunotherapy. While frequently performed through immunohistochemistry, classification was based on sequencing results in this patient, using a score derived from the percent of maximum PD-L1 expression across tested tumor samples. This method is validated in a lung cancer cohort, but accuracy in GBM is less certain. PD-L1 is expressed on the surface of most glioma cells, with increased frequency in high-grade gliomas such as GBM, and variable detection is based on technique.<sup>52-54</sup> Of note, several studies demonstrated high PD-L1 association with worse survival in GBM.<sup>55</sup>

There are no currently approved drugs that target PD-L1 in GBM, although several trials are ongoing. Given the efficacy of programmed death 1 (PD-1)/PD-L1 blockade in dMMR tumors, immunotherapy could be considered.<sup>56</sup> The PD-1 inhibitor pembrolizumab is approved for all MSI-h tumors, making it a treatment option for patients with Lynch syndrome-associated cancers, which are typically MSI-h.

#### **Rationale for Olaparib**

PARP is involved in single-strand DNA break and base excision repair. PARP-1 nuclear staining supports its

expression in GBM.<sup>57</sup> Olaparib is a PARPi that impairs the DDR, increasing treatment-induced chromosomal instability, cell cycle arrest, and apoptosis.<sup>58</sup> In patients with germline *BRCA1/2* mutations that impair double-strand DNA break repair by homologous recombination, PARPi cause synthetic lethality with significant clinical benefit.<sup>59-62</sup> PARPi also have efficacy in tumors with mutations in DDR genes, including *ATM*, and in patients with neither a germline *BRCA* mutation nor other homologous recombination deficiency.<sup>63,64</sup>

PARPi have been used as monotherapy and in combination with radiation and chemotherapy to prevent the repair of treatment-induced DNA breaks, thereby promoting tumor cell death. PARPi increase sensitivity to temozolomide in cell and xenograft models of GBM.<sup>65-67</sup> This effect persists in *MGMT* unmethylated tumors.<sup>68</sup> PARPi also restore sensitivity to temozolomide in dMMR cells.<sup>25,69</sup> In addition, exposure to temozolomide before or concurrently with a PARPi increases the magnitude of DNA damage and led to complete regression of GBM cells in one study.<sup>70</sup> This treatment-sensitizing effect is not present in patients with temozolomide resistance, which suggests optimal incorporation in newly diagnosed GBM.<sup>71</sup>

There have been 3 phase I trials of olaparib with temozolomide and/or radiation in GBM. The OPARATIC trial confirmed tumor penetration and dosing schedule, with promising early results.<sup>5,7</sup> PARADIGM-2 investigated olaparib plus radiotherapy with or without temozolomide.<sup>6,72</sup> These studies support the addition of olaparib to temozolomide and radiation as safe, well tolerated, and potentially radiosensitizing.<sup>5</sup>

## DISCUSSION

This patient had an excellent, durable response despite many factors that predict a poor prognosis. Incomplete

resection, an unmethylated *MGMT* promotor, and wild-type *IDH* are associated with exceptionally poor outcomes. In addition, somatic *MSH6* loss-of-function mutations contribute to temozolomide resistance, glioma recurrence, and tumor progression, with similar effects expected from a deleterious germline mutation. While *ATM* mutations improve treatment sensitivity, particularly with concurrent TP53 mutations, it is unlikely that this would result in a sustained, near-complete response with standard chemoradiation alone. It is also unlikely that tumor-treating fields improved clinical outcome given short duration of use.

In addition to the general chemo- and radiosensitizing properties of PARPi, the ability for PARPi to restore sensitivity to temozolomide in dMMR and *MGMT* unmethylated tumors, as well as efficacy of PARPi in DDR-deficient tumors, strongly suggests that olaparib was an essential component of the treatment regimen. The likelihood of olaparib-induced synthetic lethality is high, through impairment of single-stranded DNA break repairs in a tumor already deficient in base-base substitution, single-base insertion, and single-base deletion mismatch repair as well as double-stranded DNA break repair.

Genomic sequencing allows identification of patients with targetable mutations who may benefit from currently available treatments, which are increasing rapidly.<sup>73</sup> This is particularly important for patients predicted to have poor outcomes with standard treatment and limited access to clinical trials.

Novel treatment approaches in the first-line setting are needed. MTB discussions broaden the understanding of the interplay among complex genomic alterations and serve as a forum to share cases of successful molecular targeting to inform the care of future patients.

## AFFILIATIONS

<sup>1</sup>Division of Hematology/Oncology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC

<sup>2</sup>University of North Carolina Medical Center and University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC

<sup>3</sup>Lineberger Comprehensive Cancer Center and Department of Neurosurgery, University of North Carolina School of Medicine, Chapel Hill, NC

## CORRESPONDING AUTHOR

Simon Khagi, MD, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, 170 Manning Dr, CB#7305, Chapel Hill, NC 27599; Twitter: @DrSimonKhagi; e-mail: skhagi@med.unc.edu.

## AUTHOR CONTRIBUTIONS

**Conception and design:** All authors

**Collection and assembly of data:** All authors

**Data analysis and interpretation:** All authors

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/po/author-center](http://ascopubs.org/po/author-center).

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](http://OpenPayments)).

**Katherine P. Morgan**

**Honoraria:** Medscape, Pharmacy Times Continuing Education  
**Travel, Accommodations, Expenses:** Medscape, Pharmacy Times Continuing Education

**Simon Khagi**

**Research Funding:** Lambda Technologies

No other potential conflicts of interest were reported.

**ACKNOWLEDGMENT**

We acknowledge Jason Merker, MD, PhD; William Kim, MD; Shetal Patel MD, PhD; Amber Cipriani, PharmD; and Ashlynn Messmore, MS, for their contributions to the University of North Carolina Multidisciplinary MTB. We also acknowledge Carlos Zamora, MD, PhD, for review of the radiographic images and Scott Tomlins, MD, PhD, co-founder and chief medical officer of Strata Oncology, for providing descriptions of the sequencing methodology. We thank the patient for allowing us to share a part of her story.

**REFERENCES**

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 352:987-996, 2005
2. Kreth FW, Thon N, Simon M, et al: Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. *Ann Oncol* 24:3117-3123, 2013
3. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med* 352:997-1003, 2005
4. Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. *N Engl J Med* 360:765-773, 2009
5. Chalmers AJ, Short S, Watts C, et al: Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2. *J Clin Oncol* 36, 2018 (suppl; abstr 2018)
6. Fulton B, Short SC, James A, et al: PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. *Clin Transl Radiat Oncol* 8:12-16, 2017
7. Halford SE, Cruickshank G, Dunn L, et al: Results of the OPARATIC trial: A phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM). *J Clin Oncol* 35, 2017 (suppl; abstr 2022)
8. Stupp R, Taillibert S, Kanner A, et al: Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. *JAMA* 318:2306-2316, 2017
9. Edelmann W, Yang K, Umar A, et al: Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. *Cell* 91:467-477, 1997
10. Aarnio M, Sankila R, Pukkala E, et al: Cancer risk in mutation carriers of DNA-mismatch-repair genes. *Int J Cancer* 81:214-218, 1999
11. Meric-Bernstam F, Brusco L, Daniels M, et al: Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. *Ann Oncol* 27:795-800, 2016
12. Cahill DP, Levine KK, Betensky RA, et al: Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. *Clin Cancer Res* 13:2038-2045, 2007
13. Nguyen SA, Stechishin OD, Luchman HA, et al: Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. *Clin Cancer Res* 20:4894-4903, 2014
14. Hunter C, Smith R, Cahill DP, et al: A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. *Cancer Res* 66:3987-3991, 2006
15. Xie C, Sheng H, Zhang N, et al: Association of MSH6 mutation with glioma susceptibility, drug resistance and progression. *Mol Clin Oncol* 5:236-240, 2016
16. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 455:1061-1068, 2008 [Erratum: *Nature* 494:506, 2013]
17. Liu L, Markowitz S, Gerson SL: Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl) nitrosourea. *Cancer Res* 56:5375-5379, 1996
18. Pepponi R, Marra G, Fuggetta MP, et al: The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. *J Pharmacol Exp Ther* 304:661-668, 2003
19. Hochhauser D, Glynne-Jones R, Potter V, et al: A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. *Mol Cancer Ther* 12:809-818, 2013
20. Karran P: Mechanisms of tolerance to DNA damaging therapeutic drugs. *Carcinogenesis* 22:1931-1937, 2001
21. Aquilina G, Ceccotti S, Martinelli S, et al: N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea sensitivity in mismatch repair-defective human cells. *Cancer Res* 58:135-141, 1998
22. Stark AM, Doukas A, Hugo HH, et al: The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. *Neurol Res* 32:816-820, 2010
23. Yip S, Miao J, Cahill DP, et al: MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. *Clin Cancer Res* 15:4622-4629, 2009
24. Koi M, Umar A, Chauhan DP, et al: Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. *Cancer Res* 54:4308-4312, 1994
25. Curtin NJ, Wang LZ, Yiakouvakis A, et al: Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. *Clin Cancer Res* 10:881-889, 2004
26. Fritzell JA, Narayanan L, Baker SM, et al: Role of DNA mismatch repair in the cytotoxicity of ionizing radiation. *Cancer Res* 57:5143-5147, 1997
27. Yan T, Schupp JE, Hwang HS, et al: Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation. *Cancer Res* 61:8290-8297, 2001
28. Cercek A, Dos Santos Fernandes G, Roxburgh CS, et al: Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy. *Clin Cancer Res* 10.1158/1078-0432.CCR-19-3728 [epub ahead of print on March 6, 2020]
29. Gylling AH, Nieminen TT, Abdel-Rahman WM, et al: Differential cancer predisposition in Lynch syndrome: Insights from molecular analysis of brain and urinary tract tumors. *Carcinogenesis* 29:1351-1359, 2008
30. Hempelmann JA, Lockwood CM, Konnick EQ, et al: Microsatellite instability in prostate cancer by PCR or next-generation sequencing. *J Immunother Cancer* 6:29, 2018

31. Trabucco SE, Gowen K, Maund SL, et al: A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples. *J Mol Diagn* 21:1053-1066, 2019
32. Shia J, Holck S, Depetris G, et al: Lynch syndrome-associated neoplasms: A discussion on histopathology and immunohistochemistry. *Fam Cancer* 12:241-260, 2013
33. Shia J: Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. *J Mol Diagn* 10:293-300, 2008
34. Dudley B, Brand RE, Thull D, et al: Germline MLH1 mutations are frequently identified in Lynch syndrome patients with colorectal and endometrial carcinoma demonstrating isolated loss of PMS2 immunohistochemical expression. *Am J Surg Pathol* 39:1114-1120, 2015
35. Ivády G, Madar L, Dzsudzsák E, et al: Analytical parameters and validation of homopolymer detection in a pyrosequencing-based next generation sequencing system. *BMC Genomics* 19:158, 2018
36. AACR Project GENIE Consortium: AACR Project GENIE: Powering precision medicine through an international consortium. *Cancer Discov* 7(8):818-831, 2017
37. Pennington KP, Walsh T, Harrell MI, et al: Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. *Clin Cancer Res* 20:764-775, 2014
38. Randon G, Cucà G, Rossini D, et al: Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. *Sci Rep* 9:2858, 2019
39. Tribius S, Pidel A, Casper D: ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. *Int J Radiat Oncol Biol Phys* 50:511-523, 2001
40. Jiang H, Reinhardt HC, Bartkova J, et al: The combined status of ATM and p53 link tumor development with therapeutic response. *Genes Dev* 23:1895-1909, 2009
41. Biddlestone-Thorpe L, Sajjad M, Rosenberg E, et al: ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. *Clin Cancer Res* 19:3189-3200, 2013
42. Lord CJ, Ashworth A: PARP inhibitors: Synthetic lethality in the clinic. *Science* 355:1152-1158, 2017
43. Armstrong SA, Schultz CW, Azimi-Sadjadi A, et al: ATM dysfunction in pancreatic adenocarcinoma and associated therapeutic implications. *Mol Cancer Ther* 18:1899-1908, 2019
44. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. *Nature* 408:307-310, 2000
45. Tate JG, Bamford S, Judd HC, et al: COSMIC: The catalogue of somatic mutations in cancer. *Nucleic Acids Res* 47(D1):D941-D947, 2019
46. Li GM: Mechanisms and functions of DNA mismatch repair. *Cell Res* 18:85-98, 2008
47. Tcheleni L, Ashamalla H, Graves P: Mutant p53 and the response to chemotherapy and radiation, in Deb S, Deb S (eds): *Mutant p53 and MDM2 in Cancer. Subcellular Biochemistry*, Volume 85. Dordrecht, the Netherlands, Springer, 2014
48. Alexandrov LB, Nik-Zainal S, Wedge DC, et al: Signatures of mutational processes in human cancer. *Nature* 500:415-421, 2013 [Erratum: *Nature* 502:258, 2013]
49. Bouffett E, Larouche V, Campbell BB, et al: Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. *J Clin Oncol* 34:2206-2211, 2016
50. Salem M, Grothey A, Kim E, et al: Impact of MLH1, PMS2, MSH2, and MSH6 alterations on tumor mutation burden (TMB) and PD-L1 expression in 1,057 microsatellite instability-high (MSI-H) tumors. *J Clin Oncol* 36, 2018 (suppl; abstr 3572)
51. Campbell BB, Light N, Fabrizio D, et al: Comprehensive analysis of hypermutation in human cancer. *Cell* 171:1042-1056.e10, 2017
52. Chen RQ, Liu F, Qiu XY, et al: The prognostic and therapeutic value of PD-L1 in glioma. *Front Pharmacol* 9:1503, 2019
53. Berghoff AS, Kiesel B, Widhalm G, et al: Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. *Neuro-oncol* 17:1064-1075, 2015
54. Berghoff AS, Kiesel B, Widhalm G, et al: Correlation of immune phenotype with IDH mutation in diffuse glioma. *Neuro-oncol* 19:1460-1468, 2017
55. Xue S, Song G, Yu J: The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis. *Sci Rep* 7:4231, 2017
56. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med* 372:2509-2520, 2015
57. Galia A, Calogero AE, Condorelli R, et al: PARP-1 protein expression in glioblastoma multiforme. *Eur J Histochem* 56:e9, 2012
58. Lord CJ, Tutt AN, Ashworth A: Synthetic lethality and cancer therapy: Lessons learned from the development of PARP inhibitors. *Annu Rev Med* 66:455-470, 2015
59. Hartwell LH, Szankasi P, Roberts CJ, et al: Integrating genetic approaches into the discovery of anticancer drugs. *Science* 278:1064-1068, 1997
60. Kaelin WG Jr: The concept of synthetic lethality in the context of anticancer therapy. *Nat Rev Cancer* 5:689-698, 2005
61. Robson M, Im SA, Senkus E, et al: Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *N Engl J Med* 377:523-533, 2017
62. Golan T, Hammel P, Reni M, et al: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. *N Engl J Med* 381:317-327, 2019
63. Mirza MR, Monk BJ, Herrstedt J, et al: Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. *N Engl J Med* 375:2154-2164, 2016
64. de Bono J, Mateo J, Fizazi K, et al: Olaparib for metastatic castration-resistant prostate cancer. *N Engl J Med* 382:2091-2102, 2020
65. Tentori L, Leonetti C, Scarsella M, et al: Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. *Clin Cancer Res* 9:5370-5379, 2003
66. Boulton S, Pemberton LC, Porteous JK, et al: Potentiation of temozolomide-induced cytotoxicity: A comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. *Br J Cancer* 72:849-856, 1995
67. Delaney CA, Wang LZ, Kyle S, et al: Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. *Clin Cancer Res* 6:2860-2867, 2000
68. Yuan AL, Ricks CB, Bohm AK, et al: ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. *PLoS One* 13:e0202860, 2018
69. Higuchi F, Nagashima H, Ning J, et al: Restoration of temozolomide sensitivity by PARP inhibitors in mismatch repair deficient glioblastoma is independent of base excision repair. *Clin Cancer Res* 26:1690-1699, 2020
70. Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al: Chemopotential of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. *Mol Cancer Ther* 2:371-382, 2003
71. Clarke MJ, Mulligan EA, Grogan PT, et al: Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. *Mol Cancer Ther* 8:407-414, 2009
72. Lesueur P, Lequesne J, Grellard JM, et al: Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol. *BMC Cancer* 19:198, 2019
73. Marquart J, Chen EY, Prasad V: Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. *JAMA Oncol* 4:1093-1098, 2018



## APPENDIX

**TABLE A1.** Normal Gene Function

Gene	Function
<i>MSH6</i>	One of 4 major proteins in the DNA mismatch repair system Involved in the repair of base-base substitutions and single-base insertion or deletion mismatches Results in high susceptibility to mutations in tumor suppressor and proto-oncogenes, resulting in increased risk of many malignancies
<i>ATM</i>	Expressed in most tissues Key regulator of DNA damage response Serves as a tumor suppressor by initiating DNA damage checkpoint signaling after accumulation of double-stranded DNA breaks and initiating repair by homologous recombination
<i>TP53</i>	The most commonly mutated gene in human cancer A transcription factor that induces antitumor responses, including DNA repair and apoptosis, to cellular stress